A Billion-Dollar Ointment Giant's Growth Story Unveiled

When it comes to Lianrui Pharmaceutical, the public may not be too familiar with the company. However, its "Two Tigers" series of ointments have long been deeply rooted in people's minds, with many seeing their presence in their parents' or elders' storage spaces. This seemingly ordinary enterprise, relying on this series of "low-key" ointment products, has achieved steady revenue growth for 13 consecutive years, with net profit maintaining double-digit growth for 6 consecutive years, demonstrating a stable development trend.

The development history of Lianrui Pharmaceutical can be considered legendary. It originated in 1988 as a national poverty alleviation project in the old revolutionary base area. At the time, the company relied on a loan of 258,000 yuan to establish the Xinyang Lingyang Mountain Pharmaceutical Factory in Xinxian County, Henan, with its flagship product being the Musk and Tiger Bone Ointment. After a series of reforms and innovations, Lianrui Pharmaceutical successfully listed on the Shanghai Stock Exchange in October 2000, becoming the first listed company in the national rubber ointment drug industry, as well as the only listed company in the Xinyang region and the entire Dabie Mountain area, injecting new vitality into the regional economic development.

Today, Lianrui Pharmaceutical has transformed into a national high-tech enterprise with pharmaceutical and medical device production and operation as its core business. In terms of revenue structure, its four major product categories, including plasters, tablets, capsules, and ointments, constitute its main revenue pillars. According to the latest data, in 2023, Lianrui Pharmaceutical achieved a total revenue of 3.311 billion yuan, with its plaster products accounting for as much as 2.05 billion yuan, occupying an important market share. Notably, its products' gross profit margins in the traditional Chinese medicine industry are among the highest, with the gross profit margin of its plaster products reaching as high as 75.68%, demonstrating its strong profitability and market competitiveness.

While continuously setting new performance records, Lianrui Pharmaceutical has also performed excellently in rewarding its shareholders. In the 23 years since its listing, the company has paid dividends 21 times, with a total dividend amount of 1.582 billion yuan, and a dividend financing ratio of 146.67%, which is particularly outstanding among A-share pharmaceutical stocks, fully reflecting the company's emphasis on and commitment to shareholder interests.

In summary, Lianrui Pharmaceutical, a company that originated in an impoverished mountain region, has successfully built a leading position in the ointment field through continuous investment in its products and strong marketing capabilities. Although its products may appear ordinary on the surface, these "low-key" ointments have made Lianrui Pharmaceutical a remarkable "golden phoenix," making positive contributions to the development of the traditional Chinese medicine industry.